Drug Profile
Dusquetide - Soligenix
Alternative Names: Dusquetide; IDR-1; Innate defense regulator-1; SGX-94; SGX-942; SGX-943; SGX-945Latest Information Update: 13 Feb 2024
Price :
$50
*
At a glance
- Originator University of British Columbia
- Developer Soligenix; The Childrens Hospital of Philadelphia
- Class Anti-inflammatories; Antibacterials; Antineoplastics; Peptides; Proteins
- Mechanism of Action SQSTM1 protein modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase III Stomatitis
- Preclinical Breast cancer
- No development reported Bacterial infections; Melioidosis
- Discontinued Lymphoproliferative disorders